Loblaw, CA5394811015

Loblaw stock: Q3 sales rise as adjusted EPS gains 8.8%

Published on 11/21/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Loblaw stock enters the week after stronger retail sales and a steady 2026 outlook. Drug retail and e-commerce led operating momentum in the quarter.

Loblaw's week in focus

  • Third-quarter results showed stronger retail sales and continued high-single-digit adjusted earnings growth guidance.
  • The sale of QHR Technologies added another corporate transaction during the week.
  • Toronto trading finished the week higher than the previous Friday.
Loblaw, CA5394811015, Illustration mit AI erstellt.

On Thursday, November 19, Loblaw Companies Limited reported third-quarter results for the 16 weeks ended October 10. The company said in its Loblaw news release that retail sales rose 3.6 percent to 19,857 million Canadian dollars and adjusted diluted earnings per share increased 8.8 percent to 0.74 Canadian dollars.

Retail growth led the quarter

Drug Retail sales increased 5.7 percent, while same-store sales rose 4.8 percent. Pharmacy and healthcare services posted same-store growth of 7.6 percent, supported by specialty and chronic prescriptions. Food Retail sales grew 2.8 percent, although food same-store sales increased only 0.6 percent.

E-commerce sales advanced 16.9 percent. Loblaw opened 18 stores during the quarter, including nine hard-discount locations and seven drug stores, while closing one drug store. Retail operating income rose 9.7 percent to 1,408 million Canadian dollars.

Adjusted results frame outlook

Adjusted net earnings reached 857 million Canadian dollars, up 4.8 percent. Reported net earnings available to common shareholders were 1,193 million Canadian dollars and included a post-tax gain of 401 million Canadian dollars from the sale of PC Financial. The adjusted figures exclude that discontinued-operation gain and include only one month of income from Loblaw's investment in EQB.

Management maintained its 2026 outlook. Loblaw continues to expect adjusted earnings per common share growth in the high single digits, capital spending of about 2.4 billion Canadian dollars and significant share repurchases funded by free cash flow. The company repurchased and cancelled 8.3 million common shares during the quarter for 524 million Canadian dollars.

QHR sale adds a transaction

On Wednesday, November 18, Loblaw sold its interest in QHR Technologies to LGI Healthcare Solutions for cash consideration of approximately 236 million Canadian dollars. The gain will be recognized in the fourth quarter, according to the company's release.

Loblaw stock traded at 45.60 euros on Lang & Schwarz at 10:45 CET on Saturday, November 21.

Loblaw Companies Limited

  • ISIN: CA5394811015
  • Home exchange: Toronto Stock Exchange
  • Lang & Schwarz quote: 45.60 euros on November 21, 2026 at 10:45 CET
  • Toronto weekly change: 69.93 Canadian dollars on November 13 to 71.45 Canadian dollars on November 20, 2026, up 2.17 percent
  • Third-quarter period: 16 weeks ended October 10, 2026

Canadian market reports provide the broader trading backdrop for current market reports.

More news and analyses on Loblaw stock

Disclaimer...
en | CA5394811015 | LOBLAW | boerse | 70541801 | bgmi